Investigation of sumatriptan and ketorolac trometamol in the human experimental model of headache

Abstract

Background: Pituitary adenylate cyclase-activating polypeptide-38 (PACAP38) induces headache in healthy volunteers but the precise mechanisms by which PACAP38 leads to headache are unclear. We investigated the headache preventive effect of sumatriptan and ketorolac on PACAP38-induced headache in healthy volunteers. In addition, we explored contribution of vascular mechanisms to PACAP38-induced headache using high resolution magnetic resonance angiography. Methods: Thirty-four healthy volunteers were divided in two groups (A and B) and received infusion of PACAP38 (10 picomol/kg/min) over 20 min. Group A was pretreated with intravenous sumatriptan (4 mg) or ketorolac (30 mg) 20 min before infusion of PACAP38. Group B received infusion of sumatriptan or ketorolac as post-treatment 90 min after infusion of PACAP38. In both experiments, we used a randomized, double-blind, cross-over design. We recorded headache characteristics and circumference of extra-intracerebral arteries. Results: We found no difference in AUC (0-6 h) of PACAP38-induced headache in group A, pretreated with sumatriptan or ketorolac (p = 0.297). There was no difference between sumatriptan and ketorolac in PACAP38induced circumference change (AUC Baseline-110 min) of MMA (p = 0.227), STA (p = 0.795) and MCA (p = 0.356). In group B, post-treatment with ketorolac reduced PACAP38-headache compared to sumatriptan (p < 0.001). Posttreatment with sumatriptan significantly reduced the circumference of STA (p = 0.039) and MMA (p = 0.015) but not of MCA (p = 0.981) compared to ketorolac. In an explorative analysis, we found that pre-treatment with sumatriptan reduced PACAP38-induced headache compared to no treatment (AUC 0-90min). Conclusions: Post-treatment with ketorolac was more effective in attenuating PACAP38-induced headache compared to sumatriptan. Ketorolac exerted its effect without affecting PACAP38-induced arterial dilation, whereas sumatriptan post-treatment attenuated PACAP38-induced dilation of MMA and STA. Pre-treatment with sumatriptan attenuated PACAP38-induced headache without affecting PACAP38-induced arterial dilation. Our findings suggest that ketorolac and sumatriptan attenuated PACAP38-induced headache in healthy volunteers without vascular effects. Trial registration: Clinicaltrials.gov (NCT03585894). Registered

Infusion of Pituitary Adenylate Cyclase–Activating Polypeptide-38 in Patients with Rosacea Induces Flushing and Facial Edema that Can Be Attenuated by Sumatriptan

“…Sumatriptan has been administered in doses up to 96 micrograms/kg in experimental settings (Perrin et al 1989) with the most effective dose being 64 micrograms/kg (Perrin et al 1989), corresponding to 4.3 mg in a 67 kg person. This dose has recently been administered intravenously in healthy volunteers without any major side effects (Ghanizada et al 2020a). Sumatriptan has a bioavailability of approximately 96% with intravenous administration, and intravenous infusion of sumatriptan has previously resulted in pain relief within 10-30 minutes in patients with migraine (Perrin et al 1989) .…”

“…Every 10 mins patients were asked to remain still with closed eyes for at least 5s to obtain a scaled color-coded image with red color for high perfusion and blue color for low perfusion. The use of laser speckle contrast imaging to measure blood flow has previously been described (Briers 2001;Ghanizada et al 2020a).…”

Comparative Study of Dezocine and Ketorolac Tromethamine in Patient-Controlled Intravenous Analgesia of Laparoscopic Cholecystectomy

“…④ Ketorolac tromethamine can selectively aggregate the pain site, thus increasing the drug concentration, which makes the analgesic effect stronger, the action time longer, and the sedative effect stronger ( 21 ). ⑤ Some scholars have found that ketorolac tromethamine may have an effect on the hypothalamic prostate system In addition, its analgesic effect may be related to the synthesis and participation of nitric oxide ( 22 , 23 ). However, more experiments are needed to confirm this conclusion.…”

Pain and Management of Pain: A Clinical Review for Craniofacial Surgeons

“…It should come as no surprise, therefore, that direct topical application of local anesthetics and sumatriptan have reduced both frequency and magnitude of headaches. 3,4 The principal neurotransmitter is glutamine.…”